[8-K] Aptevo Therapeutics Inc Reports Material Event

Rhea-AI Filing Summary

Meta Platforms, Inc. (NASDAQ: META) – Form 144 filing discloses that Mark Zuckerberg intends to sell an additional 13,793 Class A common shares on or about 01 July 2025. The broker named for the transaction is Charles Schwab & Co., Inc. and the filing lists an aggregate market value of $9.98 million for the proposed sale. The shares were originally acquired via an option exercise on 17 May 2012 and will be sold on the NASDAQ exchange.

The form also details 13 prior sales executed by Mr. Zuckerberg between 06 June 2025 and 30 June 2025. During this period he disposed of approximately 124,846 shares for total gross proceeds of ≈ $89.0 million. Individual transactions ranged from 500 to 13,793 shares, with proceeds per trade between roughly $0.35 million and $10.21 million.

Key takeaways:

• Continued insider selling pattern by Meta’s Chief Executive Officer within a single quarter.
• Upcoming sale represents a small fraction (≈0.006%) of Meta’s reported 2.17 billion shares outstanding, but may signal ongoing liquidity diversification.
• Sale is being filed under Rule 144, indicating shares are not subject to a lock-up and that the insider affirms no undisclosed material information.

Positive

• Transparent disclosure: Filing under Rule 144 provides timely visibility into the CEO’s trading intentions and affirms compliance with insider-trading regulations.

Negative

• Ongoing insider selling: CEO Mark Zuckerberg has sold ≈ 124.8 k shares for ≈ $89 m in June 2025 and plans to dispose of another 13.8 k shares, a pattern that can pressure investor sentiment.

Insights

Securities Analyst

TL;DR: CEO plans further share sale; sustained insider selling trend may weigh on sentiment.

Rule 144 filings do not directly affect fundamentals, but a CEO’s repetitive sales often attract investor scrutiny. Zuckerberg has already liquidated ≈ 124.8 k shares for ≈ $89 m in June 2025 and now plans another 13.8 k shares (~$10 m). While the amount is immaterial relative to Meta’s >$1 tn market cap and 2.17 bn share count, persistent selling can create a perception of limited upside or personal diversification. No operational data accompany the filing, so the market response will hinge largely on insider-sentiment optics rather than cash-flow impact.

Corporate Governance Expert

TL;DR: Filing shows compliant, transparent use of Rule 144 but underscores governance focus on insider trading cadence.

The notice confirms that Zuckerberg attests to possessing no undisclosed adverse information and, if relying on a 10b5-1 plan, that it was adopted previously. From a governance lens, transparency is positive; however, the cadence and size of recent sales (13 transactions in June) raise monitoring needs for board committees and investors. Aggregate insider selling may influence proxy advisory recommendations if perceived as misaligned with shareholder value creation, though the use of standard brokerage and full disclosure mitigates regulatory concerns.

false000167158400016715842025-07-012025-07-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 01, 2025

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously disclosed, Aptevo Therapeutics Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the quarter ended March 31, 2025, the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on Nasdaq. On July 1, 2025, the Company received a letter from the Staff confirming that the Company has regained compliance with the Rule. The Company’s compliance was evidenced by its Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2025, which reported that, during the quarterly period ended June 30, 2025, the Company raised gross proceeds of approximately $15.9 million of additional equity capital and, as a result, believes it has stockholders’ equity of at least $2.5 million and is in compliance with the Rule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	July 1, 2025	By:	/s/ Marvin L. White
			Marvin L. White President and Chief Executive Officer

FAQ

How many Meta (META) shares does Mark Zuckerberg plan to sell in this Form 144?

The filing covers 13,793 Class A common shares scheduled for sale around 01 July 2025.

What is the estimated market value of the proposed META share sale?

The shares are valued at approximately $9.98 million based on the information provided in the Form 144.

How many Meta shares has Mark Zuckerberg sold in the past three months?

According to the filing, he sold about 124,846 shares between 06 June 2025 and 30 June 2025.

What were the total gross proceeds from Zuckerberg’s recent META share sales?

The listed transactions generated roughly $89.0 million in gross proceeds.

Which broker is executing the planned META share sale?

The broker named is Charles Schwab & Co., Inc., 3000 Schwab Way, Westlake, TX 76262.

On which exchange will the META shares be sold?

The proposed sale will take place on the NASDAQ.